Rhythm Pharmaceuticals Inc (NAS:RYTM)
$ 55.59 -0.95 (-1.68%) Market Cap: 3.47 Bil Enterprise Value: 3.14 Bil PE Ratio: 0 PB Ratio: 308.96 GF Score: 58/100

Rhythm Pharmaceuticals Inc To Discuss Hypothalamic Obesity Call Transcript

Nov 02, 2022 / 12:30PM GMT
Release Date Price: $22.9 (-12.53%)
Operator

Good day, and thank you for standing by. Welcome to the Rhythm Pharmaceuticals Conference Call on hypothalamic obesity. (Operator Instructions)

Please be advised that today's conference is being recorded.

I would now like to hand the conference over to Dave Connolly, Executive Director of Investor Relations and Corporate Communications. Please go ahead.

David Connolly
Rhythm Pharmaceuticals, Inc. - Head of IR & Corporate Communications

Thank you, Andrea, and thank you all for joining us this morning. For those of you participating via the conference call, there are accompanying slides that can be accessed and controlled by going to the events section on our Investors page at our website, ir.rhythmtx.com. This morning, we issued a press release with our Phase II data from a trial evaluated setmelanotide in hypothalamic obesity as well as the design for our Phase III trial. The press release, which is now available on our website.

Here on Slide 3, I'll remind you that this call contains remarks on future expectations, plans and

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot